Christopher D Benjamin

This inventor holds 15 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent, primarily in Immunological Therapeutics. Top assignees: Biogen, Incorporated, Biogen Idec Ma Inc., Other. Active years: 1993-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christopher D Benjamin. Retrieved from https://idiyas.com/inventor/christopher-d-benjamin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15 (Patent Applications = 1)

% Patents Active = 73.3

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 3.5

ph-index = 11

Forward Citations = 297(Granted Patents)

Company Filing History:

1 out of 834,601

Other

patents

Years Active: 1993-2013

Loading Chart...

Areas of Expertise:

Lymphotoxin Receptor

Anti-Tumor Agents

Common Gamma Chain

Monoclonal Antibody

VCAM Fusion Proteins

Immunological Disease

Endothelial Cell

Adhesion Molecules

TH1 Cell Disorders

Therapeutic Agents

Autoimmune Disease

Polypeptides

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8455445 - Methods for inhibiting lymphotoxin-β receptor signaling in TH1 cell-associated disorders (2013-06-04),

2. 7951371 - Soluble lymphotoxin-β receptor fusion protein and methods for inhibiting lymphotoxin β-receptor signaling (2011-05-31),

3. 7459537 - Anti-lymphotoxin-β receptor antibodies as anti-tumor agents (2008-12-02),

4. 7427403 - Methods for inhibiting lymphotoxin β receptor signalling (2008-09-23),

5. 7001598 - Anti-lymphotoxin-beta receptor antibodies as anti-tumor agents (2006-02-21),

6. 6770745 - Common gamma chain blocking agents (2004-08-03),

7. 6669941 - Soluble lymphotoxin-&bgr; receptor as a therapeutic agent for treating TH-1 cell-associated autoimmune disease (2003-12-30),

8. 6403087 - Soluble lymphotoxin-&bgr; receptors as therapeutic agents for the treatment of immunological disease (2002-06-11),

9. 6323027 - Common gamma chain monoclonal antibody blocking agents (2001-11-27),

10. 6312691 - Lymphotoxin-&agr;/&bgr; complexes and anti-lympotoxin-&bgr; receptor antibodies as anti-tumor agents (2001-11-06),

11. 6307025 - VCAM fusion proteins and DNA coding therefor (2001-10-23),

12. 6252043 - Vascular cell adhesion molecule (VCAM) polypeptides (2001-06-26),

13. 5925351 - Soluble lymphotoxin-.beta. receptors and anti-lymphotoxin receptor and (1999-07-20),

14. 5367056 - Endothelial cell-leukocyte adhesion molecules (ELAMs) and molecules (1994-11-22),

15. 5272263 - DNA sequences encoding vascular cell adhesion molecules (VCAMS) (1993-12-21),

Title: Christopher D Benjamin: Innovating Immunological Treatments

Introduction: Christopher D Benjamin is a prolific inventor based in Beverly, MA (US), with a remarkable portfolio of 15 patents. His groundbreaking work in developing methods for inhibiting lymphotoxin-β receptor signaling has significantly contributed to advancements in treating immunological disorders.

Latest Patents: Among his latest patents is the development of methods for inhibiting lymphotoxin-β receptor signaling in TH1 cell-associated disorders. This innovative invention involves lymphotoxin-β receptor blocking agents that are instrumental in treating lymphocyte-mediated immunological diseases, particularly in inhibiting Th1 cell-mediated immune responses. The invention encompasses soluble forms of the lymphotoxin-β receptor extracellular domain and the use of antibodies targeting the lymphotoxin-β receptor or its ligand, surface lymphotoxin.

Career Highlights: Christopher D Benjamin has made significant contributions during his tenure at esteemed companies such as Biogen, Incorporated and Biogen Idec Ma Inc. His innovative solutions have garnered recognition within the scientific community for their potential to revolutionize immunological therapies.

Collaborations: Throughout his career, Christopher D Benjamin has collaborated closely with accomplished individuals in the field, including Jeffrey L Browning and Catherine A Hession. These collaborations have been instrumental in advancing his research and bringing novel treatments to fruition.

Conclusion: Christopher D Benjamin's dedication to innovating treatments for immunological disorders is evident in his extensive patent portfolio. His contributions have the potential to transform the landscape of immunological therapies, offering new hope for patients battling these complex conditions.

Profile summary based on public USPTO records.